N/A N=327

Morbidity in Newly Diagnosed type2 Diabetes in Adults

Type2 Diabetes Mellitus · Complications

Bottom Line

View on ClinicalTrials.gov: NCT02002091 ↗

Enrolled (actual)

327

Serious AEs

2.3%

Results posted

Sep 2018

Primary outcome: Primary: Number and Prevalence of Patients With Diabetic Retinopathy — 9; 18 Participants — p=0.706

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: no specific treatment (Other)
Age: Adult, Older Adult · 40+ yrs
Sex: All
Sponsor: University of Algiers
Primary completion: Dec 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Number and Prevalence of Patients With Diabetic Retinopathy	9; 18	0.706
PRIMARY Number of Patients With Distal Diabetic Neuropathy	42; 56	0.346
PRIMARY Number of Patients With Chronic Kidney Disease (CKD)	35; 43	0.123
PRIMARY Number of Patients With Hypertension	82; 136	0.968
PRIMARY Number of Patients With Silent Myocardial Ischemia	11; 4	0.004 sig
PRIMARY Number of Patients With Lower Extremity Artery Disease	6; 12	0.988
PRIMARY Number of Patients With Carotid Artery Stenosis	7; 3	0.038 sig
PRIMARY Number of Patients With Renal Artery Stenosis or Elevated Intrarenal Resistance Index	2; 2	—
PRIMARY Number of Patients With Cardiac Autonomic Neuropathy	10; 19	0.917
PRIMARY Number of Patients With Bladder Autonomic Neuropathy	5; 11	0.816
PRIMARY Number of Patients With Gastro-intestinal Autonomic Neuropathy	0; 6	0.008 sig
PRIMARY Number of Patients With Erectile Dysfunction	63	—
SECONDARY Number of Patients With New Cardiac Events During Follow-up	7; 2	0.025 sig
SECONDARY Number of Patients With New Stroke or Transient Ischemic Attack	1; 2	—
SECONDARY Number of Patients With Lower Limbs Atherothrombotic Accident	0; 1	—
SECONDARY Number of Patients That Died From Cardio Vascular Cause	3; 2	0.059

Summary

* It is a prospective,observational, cohort study * The main purpose of the study is to assess the prevalence of diabetic chronic complications in newly diagnosed type 2 diabetics in suburban area of Algiers. * The secondary purpose is to study the impact of diabetic renal complications as a risk factor on the atherothrombotic events.

Eligibility Criteria

Inclusion Criteria

Men or women aged from 40 to 70 years
Newly diagnosed type 2 diabetes
Never treated for diabetes

Exclusion Criteria

Gestational diabetes

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02002091). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.